Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04413123 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
A Phase 2 study of Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma, sponsored by Bradley A. McGregor, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT04413123: Active Phase 2 study of Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma, sponsored by Bradley A. McGregor, MD.
NCT04413123 is a Phase 2 study of Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma that is active but no longer recruiting, run by Bradley A. McGregor, MD. The registered enrollment target is 60 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (75% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04413123, a Phase 2 study of Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Bradley A. McGregor, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other areas the body.
Primary Outcome
Percent of patients who achieve overall response (CR or PR) by RECIST 1.1 will be summarized with 80% two-sided exact binomial confidence intervals (CI)
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Cabozantinib
Study Locations (4)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Brigham & Woman's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Texas
- UT Southwestern Medical - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2026-12-20 |
| Phase | Phase 2 |
What the registry record for NCT04413123 still lists
NCT04413123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (75% lower).
The record links to 8 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04413123 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT04413123 about?
NCT04413123 is a clinical study titled "Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC". This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other areas the body.
What is the current status of trial NCT04413123?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-11-05. Estimated completion is 2026-12-20.
What conditions does trial NCT04413123 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma.
What interventions are being tested in trial NCT04413123?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04413123?
This trial is sponsored by Bradley A. McGregor, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04413123 being conducted?
This trial has 4 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04413123's enrollment target sits among peer trials
60 70th of 121 higher than 48 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI